New combo attack on tough sarcomas
NCT ID NCT05488366
Summary
This is a small, early-stage study to see if it's safe and practical to combine a targeted, high-dose radiation treatment with an immunotherapy drug (pembrolizumab) for people with advanced soft-tissue sarcoma that has spread or come back. The goal is to see if this two-part approach can help control the cancer. It is for adults whose cancer is not eligible for curative surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.